Decompensated porto-pulmonary hypertension in a cirrhotic patient with thrombosis of portocaval shunt

Chiara Giannarelli, Antonio De Giorgi, Ferdinando De Negri, Franco Carmassi

Abstract
We report a case of decompensated porto-pulmonary hypertension closely associated with the development of intra-portocaval shunt thrombosis. A woman with Laennec's cirrhosis was hospitalized because of severe dyspnea and edema. She underwent surgical portocaval anastomosis ten years ago. Imaging studies showed massive intra-shunt thrombosis, portal hypertension, ascites, pleuro-pericardial effusions and enlargement of right cardiac cavities. Cardiac catheterization allowed to rule out coronary and left-sided heart abnormalities and led to the diagnosis of pre-capillary pulmonary hypertension. Antithrombotic treatment with low molecular weight heparin was instituted. The management also included ACE inhibitors, spironolactone, low-salt diet and lactulose. The patient was discharged and three months later we observed the disappearance of edema, ascites and pleuro-pericardial effusions and improved dyspnea and liver function tests. A possible link between the development of intra-shunt thrombosis and clinical decompensation in our patient was hypothesized. In fact, it has been demonstrated that the increased portal pressure, caused by occlusion of portosystemic shunt, reduces renal plasma flow and increases systemic endothelin-1 concentration. In our patient the disappearance of edematous state and improved dyspnea observed after recanalization of the shunt strongly support this hypothesis.

© 2007 WJG. All rights reserved.

Key words: Porto-pulmonary hypertension; Porto-caval shunt; Thrombosis

Giannarelli C, De Giorgi A, De Negri F, Carmassi F. Decompensated porto-pulmonary hypertension in a cirrhotic patient with thrombosis of portocaval shunt. World J Gastroenterol 2007; 13(47): 6439-6440

http://www.wjgnet.com/1007-9327/13/6439.asp

INTRODUCTION
Porto-pulmonary hypertension (PPHT) refers to the development of pulmonary arterial hypertension in the setting of portal hypertension with or without chronic liver disease and is defined by a mean pulmonary artery pressure > 25 mmHg in the presence of normal pulmonary wedge pressure (< 15 mmHg). The pathogenesis of PPHT is under investigation, although histopathologic features are similar to those found in primary pulmonary hypertension. A current study supports the hypothesis that pulmonary vasculature may be exposed to either cytokines or excess circulating vasoconstrictors, such as endothelin-1 (ET-1) produced by the diseased liver. Although the vast majority of patients with PPHT are asymptomatic, dyspnea is the most frequent presenting symptom.

CASE REPORT
A 39-year-old obese woman with Laennec’s cirrhosis (Child-Pugh B) was admitted to our hospital in January 2003 because of the recent onset of dyspnea (NYHA IV), dependent edema and abdominal pain. In 1991, she underwent surgical side to side portocaval shunt for refractory ascites and since then she has never complained of dyspnea or edema. Physical examination showed platypnea, arterial blood gas analysis showed hypoxaemia (pO2: 63 mmHg) with orthodeoxia (pO2: 49 mmHg). On admission, liver function tests were as follows: total bilirubin: 84.5 µmol/L, AST: 1.14 µkat/L, ALT: 0.55 µkat/L, GGT: 87 U/L, alkaline phosphatase: 4.2 nkat/L, serum albumin: 28 g/L, ammonia (as NH3): 88 µmol/L, prothrombin time 60%. Hepatic ultrasonography with Doppler imaging showed massive intra-shunt thrombosis, portal hypertension (18 mmHg) and mild ascites. No gastroesophageal varices were found by digestive endoscopy. D-dimer level was 1.4 mg/L and antithrombin activity was 43%. The presence of both peripheral venous thrombosis and recurrent microembolism was ruled out by Doppler ultrasonography and ventilation-perfusion lung scan. Computed tomography confirmed recent intra-shunt thrombosis and showed also pleuro-pericardial effusions and ascites. Markers of autoimmunity were negative.

Right atrial and ventricular enlargement with severe
The development of intra-shunt thrombosis and clinical decompensation in our patient. In fact, a recent study showed that increased portal pressure caused by occlusion of porto-systemic shunt reduces renal plasma flow, leading to renal sodium and water retention, and increases systemic ET-1 concentration. In our patient, disappearance of edema and improved dyspnea, observed after recanalization of the shunt, strongly support this hypothesis, although further experience with similar cases is needed.

REFERENCES

1. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100: 520-528
2. Simonneau G, Galie N, Rubin LJ, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S
3. Passarella M, Fallon MB, Kawut SM. Portopulmonary hypertension. Clin Liver Dis 2006; 10: 653-663
4. Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003; 9: 32-39
5. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498
6. Tam NL, He XS. Clinical management of portopulmonary hypertension. Hepatobiliary Pancreat Dis Intl 2007; 6: 464-469

S- Editor Liu Y  L- Editor Wang XL  E- Editor Ma WH